ArticleJournal of genetic counseling2017
Large, Prospective Analysis of the Reasons Patients Do Not Pursue BRCA Genetic Testing Following Genetic Counseling.
Article in Journal of genetic counseling, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Patient perspectives on risk-reducing salpingectomy with delayed oophorectomy for ovarian cancer risk-reduction: A systematic review of the literature.Gynecologic oncology · 2023Pooled it
- Cascade Testing for Hereditary Cancer Syndromes: Should We Move Toward Direct Relative Contact? A Systematic Review and Meta-Analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Pooled it
- Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis.Gynecologic oncology · 2021Pooled it
- Understanding Barriers and Motivators of Familial Hypercholesterolemia Genetic Testing: Insights From the Singapore Public.Journal of genetic counseling · 2026Article
- Cancer genetic testing uptake in the primary care setting: Patient perspectives on barriers and facilitators throughout the testing process.Journal of genetic counseling · 2026Article
- Barriers and motivators for BRCA genetic testing in Japan.Journal of genetic counseling · 2026Article
- Interest in Genetic Testing for Hereditary Cancer Risk: Associations with Genetic Familiarity, Self-Efficacy, and Sociodemographics.Public health genomics · 2026Article
- Improving genetics equity: identifying women eligible for genetic care services using mammography clinics in underserved areas as screening hubs.The oncologist · 2025Article
- Genetic counseling referral rates and genetic testing outcomes in women with young breast cancer: a 20-year Canadian review.Breast cancer research and treatment · 2025Article
- Impact of barriers and motivators on intention and confidence to undergo hereditary cancer genetic testing.Journal of genetic counseling · 2025Article
- Barriers to early detection: Insurance denials for breast MRI screening in women with germline BRCA1/2 mutations.Gynecologic oncology · 2025Article
- The Role of Demographic and Clinical Factors in Germline Mutation Testing for Patients with Primary Hyperparathyroidism.Annals of surgical oncology · 2024Article
- Promoters of BRCA testing under insurance coverage for non-metastatic breast cancer patients in Japan: a retrospective cohort study.Breast cancer (Tokyo, Japan) · 2023Article
- Toward a More Just System of Care in Molecular Pathology.The Milbank quarterly · 2022Article
- Uptake of genetic counseling and testing in a clinic-based population of women with breast cancer.Cancer medicine · 2022Article
- Financial constraints on genetic counseling and further risk-management decisions among U.S. women at elevated breast cancer risk.Journal of genetic counseling · 2021Article
- Knowledge and perceptions of BRCA1/2 genetic testing and needs of diverse women with a personal or family history of breast cancer in South Florida.Journal of community genetics · 2021Article
- Impact of changing guidelines on genetic testing and surveillance recommendations in a contemporary cohort of breast cancer survivors with family history of pancreatic cancer.Scientific reports · 2021Article
- Challenges of Genomic Testing for Hereditary Breast and Ovarian Cancers.The application of clinical genetics · 2021Review
- Utilization of genetic testing in breast cancer treatment after implementation of comprehensive multi-disciplinary care.The breast journal · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetic counseling (GC) and genetic testing (GT) identifies high-risk individuals who benefit from enhanced medical management. Not all individuals undergo GT following GC and understanding the reasons why can impact clinical efficiency, reduce GT costs through appropriate identification of high-risk individuals, and demonstrate the value of pre-GT GC. A collaborative project sponsored by the Michigan Department of Health and Human Services prospectively collects anonymous data on BRCA-related GC visits performed by providers in Michigan, including demographics, patient/family cancer history, GT results, and reasons for declining GT. From 2008 to 2012, 10,726 patients underwent GC; 3476 (32.4%) did not pursue GT. Primary reasons included: not the best test candidate (28.1%), not clinically indicated (23.3%), and insurance/out of pocket cost concerns (13.6%). Patient disinterest was the primary reason for declining in 17.1%. Insurance/out of pocket cost concerns were the primary reason for not testing in 13.4% of untested individuals with private insurance. Among untested individuals with breast and/or ovarian cancer, 22.5% reported insurance/out of pocket cost concerns as the primary reason for not testing and 6.6% failed to meet Medicare criteria. In a five-year time period, nearly one-third of patients who underwent BRCA GC did not pursue GT. GT was not indicated in almost half of patients. Insurance/out of pocket cost concerns continue to be barriers.
Indexed as
Identifiers
28093663What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.